- Home
- BLRX vs EYEN Comparison
BLRX vs EYEN Comparison
Compare BLRX & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- EYEN
- Stock Information
- Founded
- BLRX 2003
- EYEN 2014
- Country
- BLRX Israel
- EYEN United States
- Employees
- BLRX N/A
- EYEN N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- EYEN Health Care
- Exchange
- BLRX Nasdaq
- EYEN Nasdaq
- Market Cap
- BLRX 36.0M
- EYEN 38.2M
- IPO Year
- BLRX 2011
- EYEN 2018
- Fundamental
- Price
- BLRX $0.48
- EYEN $0.10
- Analyst Decision
- BLRX Strong Buy
- EYEN Buy
- Analyst Count
- BLRX 2
- EYEN 3
- Target Price
- BLRX $11.50
- EYEN $12.00
- AVG Volume (30 Days)
- BLRX 407.5K
- EYEN 3.7M
- Earning Date
- BLRX 11-29-2024
- EYEN 11-12-2024
- Dividend Yield
- BLRX N/A
- EYEN N/A
- EPS Growth
- BLRX N/A
- EYEN N/A
- EPS
- BLRX N/A
- EYEN N/A
- Revenue
- BLRX $17,048,000.00
- EYEN $31,832.00
- Revenue This Year
- BLRX N/A
- EYEN $50,943.04
- Revenue Next Year
- BLRX N/A
- EYEN $397.57
- P/E Ratio
- BLRX N/A
- EYEN N/A
- Revenue Growth
- BLRX N/A
- EYEN 2557.10
- 52 Week Low
- BLRX $0.39
- EYEN $0.09
- 52 Week High
- BLRX $1.93
- EYEN $2.57
- Technical
- Relative Strength Index (RSI)
- BLRX 53.32
- EYEN 18.14
- Support Level
- BLRX $0.40
- EYEN $0.46
- Resistance Level
- BLRX $0.46
- EYEN $0.51
- Average True Range (ATR)
- BLRX 0.03
- EYEN 0.05
- MACD
- BLRX 0.01
- EYEN -0.03
- Stochastic Oscillator
- BLRX 94.50
- EYEN 3.11
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.